Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease

Inclusion Criteria:

- Persons with age-related MCI or AD according to clinical diagnosis, consistent with
National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria

- Community-dwelling controls

- Age > 55 years

- Have been enrolled and completed at least one visit in the Bio-AD study and consent to
access their data (the Rocky Mountain Alzheimer's Disease Center Bio-AD study
(clinicaltrials.gov identifier: NCT02612376))

- Have capacity to provide consent; capacity will be assessed at the time of consent

- Ability to complete baseline assessments

- Has informant (study partner) available to complete functional interviews/survey
measures

Exclusion Criteria:

- Presence of concomitant medical, neurological, or psychiatric illness or condition
that in the opinion of the investigators would confound interpretation of study
results. These include:

- Korsakoff encephalopathy;

- active substance abuse;

- hepatitis C;

- opportunistic brain infection;

- brain tumor;

- active neoplastic disease (skin tumors other than melanoma are not exclusionary;
participants with stable prostate cancer may be included at the discretion of the
project director);

- multiple sclerosis;

- history of clinically significant stroke;

- current evidence or history in the past 2 years of

- focal brain lesion,

- head injury with loss of consciousness in the past year, or

- DSM-5 criteria for any major psychiatric disorder, including

1. psychosis,

2. uncontrolled major depression,

3. bipolar disorder,

4. alcohol or substance abuse;

5. blindness,

6. deafness or

7. any other disability which may prevent the participant from participating or
cooperating in the protocol.

- Prisoners

- Any contraindication for MRI